Medicare AdvantagePrior AuthMedium impact
Leqselvi™ (deuruxolitinib) (New)
Humana·Dermatology, Family Medicine, General Practice +1 more·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has established a new prior authorization policy for Leqselvi (deuruxolitinib), a JAK inhibitor medication for treating severe alopecia areata. Prior authorization will be required starting May 27, 2026, with specific criteria including at least 50% scalp hair loss for more than 6 months and trial/contraindication of corticosteroids or cyclosporine.
Action Required
Before May 27, 2026: Update prior authorization workflow to include Leqselvi (deuruxolitinib) for Humana Medicare Advantage patients. Train staff on the two required criteria: diagnosis of severe alopecia areata with at least 50% scalp hair loss measured by SALT tool for more than 6 months, and previous trial or contraindication of corticosteroids or cyclosporine. Update pharmacy prior authorization forms and EMR templates to capture this documentation. Claims will be denied without proper prior authorization.